Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that finasteride may reduce the aggressiveness and invasion of prostate tumors, with effects potentially differing based on the androgen responsiveness of the patient's prostate cells.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This retrospective cohort study found that patients using 5α-reductase inhibitors had reduced bladder cancer-related mortality compared to nonusers, with no significant effect on bladder cancer recurrence or upper tract urothelial carcinoma mortality.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This review highlights the traditional use and potential therapeutic activities of Asiasari Radix in drug discovery, but it reports no new clinical results.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

This review found that patients taking antiandrogens, 5 alpha-reductase inhibitors, and spironolactone have an increased risk of developing gynecomastia, potentially due to hormonal changes.

This review summarizes the association between 5-alpha reductase inhibitors and depression, discussing potential mechanisms such as neuroactive steroid alterations and neuroinflammation, but reports no new clinical results.

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study found that chronic administration of finasteride affected the isotopic composition of testosterone and nandrolone metabolites, impacting the drug-testing outcomes in athletic contexts.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.

This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This study suggests that 5-alpha-reductase inhibitors may reduce the rate of clinical progression in men with low-risk prostate cancer who choose active surveillance.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.